TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

GVOKE HYPOPEN

GLUCAGON
Metabolic Approved 2019-09-10
2
Indications
--
Phase 3 Trials
6
Years on Market

Details

Status
Prescription
First Approved
2019-09-10
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: GLUCAGON

GVOKE HYPOPEN Approval History

Loading approval history...

What GVOKE HYPOPEN Treats

1 indications

GVOKE HYPOPEN is approved for 1 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypoglycemia
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GVOKE HYPOPEN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Glucagon for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: • for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. • as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. 1.1 Severe Hypoglycemia Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. 1.2 Diagnostic Aid Glucagon for Injection is indicated as a diagnostic aid for use during radiologic exami...

GVOKE HYPOPEN Patents & Exclusivity

Latest Patent: Apr 2036

Patents (18 active)

US9649364 Expires Apr 22, 2036
US11590205 Expires Apr 22, 2036
+ 8 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.